OUP user menu

De Novo CD5+ Diffuse Large B-Cell Lymphomas
A Heterogeneous Group Containing an Unusual Form of Splenic Lymphoma

Steven H. Kroft MD, Michael S. Howard MD, Louis J. Picker MD, M. Qasim Ansari MD, Deborah B. Aquino MD, Robert W. McKenna MD
DOI: http://dx.doi.org/10.1309/RM1Q-1T0B-WKQB-AF5A 523-533 First published online: 1 October 2000


We reviewed our institutional experience with de novo CD5+, large B-cell lymphomas to determine whether they represent a distinct entity and are related to CD5+ small B-cell disorders. We identified 13 cases with multiparameter flow cytometry over a period of 58 months (5% of large B-cell lymphomas) in 7 females and 6 males. Three groups were identified. Group 1 (2 cases) had diffuse splenic red pulp involvement with a distinctive cordal pattern of infiltration, no other clinical evidence of mass disease, microscopic disseminated disease on further workup, and an identical immunoglobulin-negative immunophenotype. Group 2 cases (7 cases) were clinically and morphologically heterogeneous and had an immunophenotype resembling mantle cell lymphoma (FMC7-positive, CD23–). Group 3 (4 cases) had miscellaneous immunophenotypes, including one closely resembling chronic lymphocytic leukemia. Cyclin D1 was positive in only 1 of 10 evaluable cases (group 2). We conclude that CD5+ diffuse large B-cell lymphomas are heterogeneous; most cases do not seem to be related to chronic lymphocytic leukemia or mantle cell lymphoma. However, we identified a subgroup of primary splenic CD5+ large B-cell lymphoma with diffuse red pulp involvement and believe this may represent a distinct clinicopathologic entity.

Key Words:
  • Large cell lymphoma
  • Splenic lymphoma
  • CD5
  • Mantle cell lymphoma
  • Cyclin D1